U.S. Markets closed

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
70.82+0.71 (+1.01%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close70.11
Open72.48
Bid70.64 x 1100
Ask70.84 x 1100
Day's Range70.10 - 75.56
52 Week Range14.80 - 126.90
Volume515,312
Avg. Volume1,135,968
Market Cap4.429B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Will Beam Therapeutics Inc. (BEAM) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will Beam Therapeutics Inc. (BEAM) Report Negative Q1 Earnings? What You Should Know

    Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Baron Health Care Fund: “Beam Therapeutics (BEAM) has a Unique Platform Technology”
    Insider Monkey

    Baron Health Care Fund: “Beam Therapeutics (BEAM) has a Unique Platform Technology”

    Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a […]

  • 3 Exciting Biotech Stocks to Buy Right Now
    Motley Fool

    3 Exciting Biotech Stocks to Buy Right Now

    Intellia Therapeutics (NASDAQ: NTLA), Beam Therapeutics (NASDAQ: BEAM), and Twist Bioscience (NASDAQ: TWST) are all carving niches for themselves in that industry, adding to what we know about the human genome and using that knowledge in an attempt to fight some of the most stubborn diseases. Genetic medicine is a broad field, but ultimately it comes down to a relatively simple premise.